Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PAHC
stocks logo

PAHC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
355.64M
+15%
0.670
+24.06%
364.42M
+4.78%
0.693
+10.04%
381.68M
+0.79%
0.657
+15.19%
Estimates Revision
The market is revising Upward the revenue expectations for Phibro Animal Health Corporation (PAHC) for FY2026, with the revenue forecasts being adjusted by 0.46% over the past three months. During the same period, the stock price has changed by 3.35%.
Revenue Estimates for FY2026
Revise Upward
up Image
+0.46%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+3.9%
In Past 3 Month
Stock Price
Go Up
up Image
+3.35%
In Past 3 Month
Wall Street analysts forecast PAHC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAHC is 39.75 USD with a low forecast of 27.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast PAHC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAHC is 39.75 USD with a low forecast of 27.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
1 Sell
Hold
Current: 40.770
sliders
Low
27.00
Averages
39.75
High
50.00
Current: 40.770
sliders
Low
27.00
Averages
39.75
High
50.00
JPMorgan
NULL -> Overweight
upgrade
$45 -> $50
2025-11-07
Reason
JPMorgan
Price Target
$45 -> $50
2025-11-07
upgrade
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Phibro Animal Health to $50 from $45 and keeps an Overweight rating on the shares.
Morgan Stanley
Equal Weight
maintain
$34 -> $45
2025-11-07
Reason
Morgan Stanley
Price Target
$34 -> $45
2025-11-07
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Phibro Animal Health to $45 from $34 and keeps an Equal Weight rating on the shares.
BNP Paribas Exane
Navann Ty
Neutral
maintain
$24 -> $37
2025-09-04
Reason
BNP Paribas Exane
Navann Ty
Price Target
$24 -> $37
2025-09-04
maintain
Neutral
Reason
BNP Paribas Exane analyst Navann Ty raised the firm's price target on Phibro Animal Health to $37 from $24 and keeps a Neutral rating on the shares.
BofA
Michael Ryskin
Underperform
maintain
$19 -> $27
2025-08-29
Reason
BofA
Michael Ryskin
Price Target
$19 -> $27
2025-08-29
maintain
Underperform
Reason
BofA analyst Michael Ryskin raised the firm's price target on Phibro Animal Health to $27 from $19 and keeps an Underperform rating on the shares. The firm increased EPS estimates based on the company's initial FY26 guidance that came in "well ahead" of Street consensus and raised the multiple to reflect the stronger performance, but continues to believe that growth will soon moderate and return to historical levels with limited operating leverage once M&A is annualized, the analyst tells investors.
JPMorgan
Ekaterina Knyazkova
Neutral -> Overweight
upgrade
$25 -> $35
2025-07-07
Reason
JPMorgan
Ekaterina Knyazkova
Price Target
$25 -> $35
2025-07-07
upgrade
Neutral -> Overweight
Reason
JPMorgan analyst Ekaterina Knyazkova upgraded Phibro Animal Health to Overweight from Neutral with a price target of $35, up from $25. The firm says the company continues to deliver strong results while the integration of the Zoetis medicated feed additive business is exceeding expectations. Solid animal health portfolio trends should continue, supported by strong customer demand and healthy industry fundamentals, the analyst tells investors in a research note. JPMorgan sees a favorable setup from here.
Morgan Stanley
Equal Weight
maintain
$21 -> $26
2025-06-25
Reason
Morgan Stanley
Price Target
$21 -> $26
2025-06-25
maintain
Equal Weight
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Phibro Animal Health Corp (PAHC.O) is 14.61, compared to its 5-year average forward P/E of 13.69. For a more detailed relative valuation and DCF analysis to assess Phibro Animal Health Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
13.69
Current PE
14.61
Overvalued PE
16.85
Undervalued PE
10.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
9.14
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
10.77
Undervalued EV/EBITDA
7.51

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.77
Current PS
0.00
Overvalued PS
1.01
Undervalued PS
0.54
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PAHC News & Events

Events Timeline

(ET)
2025-11-05
18:06:42
Phibro Animal Health projects FY26 EPS between $2.64 and $2.81, in line with consensus of $2.63
select
2025-11-05
18:05:52
Phibro Animal Health Announces Q1 EPS of 73c, Exceeding Consensus Estimate of 60c
select
2025-10-30 (ET)
2025-10-30
13:02:17
Phibro Animal Health Unveils Nationwide Release of Restoris Dental Gel
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-28NASDAQ.COM
ETF Movers for Friday: SILJ, IHE

  • ETF Performance: The iShares U.S. Pharmaceuticals ETF is underperforming, down approximately 0.9% in Friday afternoon trading.

  • Weakest Components: Key contributors to the ETF's decline include Eli Lilly and Phibro Animal Health, both down about 2.4% on the day.

  • Market Context: The article provides insights into the performance of specific ETFs and their components, reflecting broader market trends.

  • Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.

[object Object]
Preview
8.0
11-24NASDAQ.COM
Upcoming Ex-Dividend Dates for Phibro Animal Health, Loews, and Voya Financial

  • Upcoming Ex-Dividend Dates: On 11/26/25, Phibro Animal Health Corp. (PAHC), Loews Corp. (L), and Voya Financial Inc. (VOYA) will trade ex-dividend, with respective dividends of $0.12, $0.0625, and $0.47 scheduled for payment on 12/17/25, 12/9/25, and 12/29/25.

  • Expected Price Adjustments: Following the ex-dividend dates, PAHC shares are expected to open 0.29% lower, L shares 0.06% lower, and VOYA shares 0.68% lower, based on their recent stock prices.

  • Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 1.15% for PAHC, 0.23% for L, and 2.72% for VOYA, indicating varying levels of dividend stability.

  • Current Stock Performance: As of Monday trading, shares of PAHC, L, and VOYA have seen increases of approximately 2%, 1.4%, and 1.4%, respectively.

[object Object]
Preview
2.0
11-21NASDAQ.COM
Zacks.com Spotlights Phibro Animal Health, Astronics, CommScope, and Heritage Insurance

  • Stocks Near 52-Week Highs: The article highlights four stocks—Phibro Animal Health, Astronics, CommScope, and Heritage Insurance—that are trading near their 52-week highs and are expected to continue their upward momentum, despite concerns about potential overvaluation.

  • Phibro Animal Health: The company is experiencing strong growth in its Animal Health business, bolstered by strategic acquisitions and investments in vaccine manufacturing, leading to a positive earnings outlook.

  • Astronics: Benefiting from increased global demand in defense and commercial aerospace, Astronics has expanded its product portfolio through acquisitions, which is expected to enhance its sales and earnings in the near term.

  • CommScope and Heritage Insurance: CommScope is innovating in 5G technology solutions, while Heritage Insurance focuses on optimizing its insurance portfolio and investing in technology to manage risks effectively, both showing promising earnings growth potential.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Phibro Animal Health Corp (PAHC) stock price today?

The current price of PAHC is 40.77 USD — it has decreased -1.5 % in the last trading day.

arrow icon

What is Phibro Animal Health Corp (PAHC)'s business?

Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

arrow icon

What is the price predicton of PAHC Stock?

Wall Street analysts forecast PAHC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAHC is 39.75 USD with a low forecast of 27.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Phibro Animal Health Corp (PAHC)'s revenue for the last quarter?

Phibro Animal Health Corp revenue for the last quarter amounts to 363.89M USD, increased 39.73 % YoY.

arrow icon

What is Phibro Animal Health Corp (PAHC)'s earnings per share (EPS) for the last quarter?

Phibro Animal Health Corp. EPS for the last quarter amounts to 0.65 USD, increased 282.35 % YoY.

arrow icon

What changes have occurred in the market's expectations for Phibro Animal Health Corp (PAHC)'s fundamentals?

The market is revising Upward the revenue expectations for Phibro Animal Health Corporation (PAHC) for FY2026, with the revenue forecasts being adjusted by 0.46% over the past three months. During the same period, the stock price has changed by 3.35%.
arrow icon

How many employees does Phibro Animal Health Corp (PAHC). have?

Phibro Animal Health Corp (PAHC) has 2475 emplpoyees as of December 05 2025.

arrow icon

What is Phibro Animal Health Corp (PAHC) market cap?

Today PAHC has the market capitalization of 1.65B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free